Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Tax Provisions (2019 - 2025)

Catalyst Pharmaceuticals (CPRX) has disclosed Tax Provisions for 7 consecutive years, with $19.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Tax Provisions rose 5.25% year-over-year to $19.2 million, compared with a TTM value of $69.2 million through Dec 2025, up 32.11%, and an annual FY2025 reading of $69.2 million, up 32.11% over the prior year.
  • Tax Provisions was $19.2 million for Q4 2025 at Catalyst Pharmaceuticals, up from $18.3 million in the prior quarter.
  • Across five years, Tax Provisions topped out at $29.7 million in Q4 2023 and bottomed at -$10.2 million in Q4 2022.
  • Average Tax Provisions over 5 years is $9.0 million, with a median of $7.2 million recorded in 2022.
  • The sharpest move saw Tax Provisions soared 506.52% in 2021, then crashed 391.84% in 2022.
  • Year by year, Tax Provisions stood at $3.5 million in 2021, then tumbled by 391.84% to -$10.2 million in 2022, then surged by 390.12% to $29.7 million in 2023, then tumbled by 38.5% to $18.2 million in 2024, then grew by 5.25% to $19.2 million in 2025.
  • Business Quant data shows Tax Provisions for CPRX at $19.2 million in Q4 2025, $18.3 million in Q3 2025, and $17.2 million in Q2 2025.